Sarepta Q4 net product revenue $638.2M (+75% YoY); ELEVIDYS $384.2M; GAAP net income $159M

Sarepta Therapeutics, Inc.

2024-FY EPS reported $2.34 revenue$1,901,979,000

Q4 net product revenue $638.2M (+75% YoY); ELEVIDYS contributed $384.2M; royalty from Roche $4.9M.
GAAP net income $159.0M ($1.50 diluted EPS); non-GAAP net income $206.0M ($1.90 EPS).
Full-year 2024 total revenues $1.9B (+53% YoY); GAAP net income $235.2M vs $536M net loss in 2023.
2025 net product revenue guidance $2.9B-$3.1B (70% YoY growth); ELEVIDYS expected to grow 162%.
Closed Arrowhead licensing deal for 4 clinical-stage siRNA programs; established $600M revolving credit facility.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.